– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – –.
Head to Head Review: Aileron Therapeutics (NASDAQ:ALRN) & Eli Lilly and Company (NYSE:LLY) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Drugmakers showcase prowess in innovation chinadaily.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinadaily.com.cn Daily Mail and Mail on Sunday newspapers.
Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.
Junshi Biosciences Announces Toripalimab s NDA Accepted by the Singapore Health Sciences Authority wahanariau.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wahanariau.com Daily Mail and Mail on Sunday newspapers.